Akebia Therapeutics (AKBA) Change in Accured Expenses (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Change in Accured Expenses of $2.0 million for Q1 2026, down 26.56% year-over-year from $2.8 million in Q1 2025, and down 85.39% quarter-over-quarter from $13.9 million in Q4 2025.
Akebia Therapeutics (AKBA) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Change in Accured Expenses for 14 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 26.56% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $47.8 million (up 848.48% YoY), while the FY2025 annual figure was $48.5 million, up 479.82% from the prior year.
- Change in Accured Expenses declined to $2.0 million in Q1 2026 per AKBA's latest filing, from $13.9 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $16.0 million in Q2 2025 and bottomed at -$26.8 million in Q2 2022.
- Historically, Change in Accured Expenses has averaged -$602235.3 across 5 years, with a median of $2.8 million in 2025.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 440.04% — and 2025, when it soared 2984.2%.
- Akebia Therapeutics' Change in Accured Expenses stood at -$16.5 million in 2022, then soared by 122.55% to $3.7 million in 2023, then jumped by 31.26% to $4.9 million in 2024, then surged by 185.7% to $13.9 million in 2025, then plunged by 85.39% to $2.0 million in 2026.
- Business Quant data shows AKBA's Change in Accured Expenses at $2.0 million in Q1 2026, $13.9 million in Q4 2025, and $15.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Akebia Therapeutics | 247.98 Mn | 92.43 Mn | 38.70 Mn | -5.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.44 Mn |
| Jun 30, 2026 | -5.44 Mn |
| Mar 31, 2026 | 2.04 Mn |
| Mar 31, 2026 | 2.04 Mn |
| Dec 31, 2025 | 13.93 Mn |
| Dec 31, 2025 | 13.93 Mn |
| Sep 30, 2025 | 15.82 Mn |
| Sep 30, 2025 | 15.82 Mn |
| Jun 30, 2025 | 16.01 Mn |
| Jun 30, 2025 | 16.01 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Dec 31, 2024 | 4.88 Mn |
| Sep 30, 2024 | -3.13 Mn |
| Sep 30, 2024 | -3.13 Mn |
| Jun 30, 2024 | 519,000.00 |
| Jun 30, 2024 | 519,000.00 |
| Mar 31, 2024 | -15.05 Mn |
| Mar 31, 2024 | -15.05 Mn |